Today, JPMorgan Chase & Co. Analysts Give Eli Lilly and Co. (LLY) a $85.00 Price Target

Today, JPMorgan Chase & Co. Analysts Give Eli Lilly and Co. (LLY) a $85.00 Price Target

Eli Lilly and Co. (NYSE:LLY) has been given a $85.00 price target by JPMorgan Chase & Co. in a research note issued to investors on Thursday. The brokerage presently has a “buy” rating on the stock. JPMorgan Chase & Co.’s price target suggests a potential upside of 22.97% from the company’s current price.

A number of other research analysts also recently issued reports on LLY. BMO Capital Markets reiterated a “buy” rating and issued a $94.00 price target on shares of Eli Lilly and in a report on Wednesday, July 27th. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 price target on the stock in a report on Friday, July 29th. Argus boosted their target price on Eli Lilly and from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Tuesday, August 2nd. Citigroup Inc. restated a “buy” rating on shares of Eli Lilly and in a research note on Wednesday, August 3rd. Finally, Leerink Swann restated an “outperform” rating and set a $105.00 target price on shares of Eli Lilly and in a research note on Saturday, August 13th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Eli Lilly and has a consensus rating of “Buy” and a consensus target price of $92.34.

Eli Lilly and (NYSE:LLY) traded up 1.65% on Thursday, hitting $69.12. The stock had a trading volume of 8,620,682 shares. The company has a 50 day moving average price of $76.69 and a 200-day moving average price of $77.92. Eli Lilly and has a 52-week low of $64.18 and a 52-week high of $88.16. The company has a market cap of $73.11 billion, a price-to-earnings ratio of 30.07 and a beta of 0.28.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 25th. The company reported $0.88 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.96 by $0.08. Eli Lilly and had a net margin of 11.73% and a return on equity of 23.71%. The company earned $5.19 billion during the quarter, compared to analysts’ expectations of $4.23 billion. During the same quarter in the prior year, the business posted $0.89 earnings per share. The company’s revenue was up 4.7% compared to the same quarter last year. On average, equities research analysts predict that Eli Lilly and will post $3.55 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 9th. Stockholders of record on Tuesday, November 15th will be issued a $0.51 dividend. The ex-dividend date of this dividend is Thursday, November 10th. This represents a $2.04 annualized dividend and a dividend yield of 2.95%. Eli Lilly and’s dividend payout ratio (DPR) is presently 88.70%.

In related news, insider Maria A. Crowe sold 2,248 shares of the company’s stock in a transaction dated Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total value of $182,919.76. Following the completion of the transaction, the insider now owns 94,319 shares of the company’s stock, valued at approximately $7,674,737.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.20% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in LLY. Iowa State Bank acquired a new position in Eli Lilly and during the second quarter worth $104,000. PineBridge Investments L.P. boosted its position in Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock worth $108,000 after buying an additional 920 shares during the last quarter. Tradewinds Capital Management LLC boosted its position in Eli Lilly and by 22.3% in the third quarter. Tradewinds Capital Management LLC now owns 1,345 shares of the company’s stock worth $108,000 after buying an additional 245 shares during the last quarter. Integrated Wealth Management boosted its position in Eli Lilly and by 3.7% in the third quarter. Integrated Wealth Management now owns 1,389 shares of the company’s stock worth $112,000 after buying an additional 50 shares during the last quarter. Finally, Financial Architects Inc boosted its position in Eli Lilly and by 4.5% in the third quarter. Financial Architects Inc now owns 1,423 shares of the company’s stock worth $114,000 after buying an additional 61 shares during the last quarter. 75.11% of the stock is owned by institutional investors.

Eli Lilly and Company Profile

Related posts

Leave a Comment